Rocket Pharmaceuticals Inc (RCKT)
$17.55
Live
Performance
- $17.47$18.87$17.55
0.46%
Downside
Day's Volatility :7.42%
Upside
7.0%
- $15.98$32.53$17.55
8.97%
Downside
52 Weeks Volatility :50.88%
Upside
46.04%
Returns
| Period | Rocket Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -21.84% | 3.6% | 0.0% |
6 Months | -21.16% | 10.2% | 0.0% |
1 Year | 11.89% | 19.6% | 0.0% |
3 Years | -35.04% | 16.8% | -23.0% |
Highlights
Market Capitalization | 1.7B |
Book Value | $4.23 |
Earnings Per Share (EPS) | -2.77 |
Wall Street Target Price | 43.36 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -37.13% |
Return On Equity TTM | -64.31% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -261.5M |
Diluted Eps TTM | -2.77 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.84 |
EPS Estimate Next Year | -2.67 |
EPS Estimate Current Quarter | -0.72 |
EPS Estimate Next Quarter | -0.72 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 147.07%
Technicals Summary
Sell
Neutral
Buy
Rocket Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Rocket Pharmaceuticals Inc | -4.85% | -21.16% | 11.89% | -35.04% | 37.88% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Rocket Pharmaceuticals Inc | NA | NA | NA | -2.84 | -0.64 | -0.37 | NA | 4.23 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Rocket Pharmaceuticals Inc | Buy | $1.7B | 37.88% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Rocket Pharmaceuticals Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 73.2%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 79.8%
Institutional Holdings
RTW INVESTMENTS, LLC
19.44%Wellington Management Company LLP
10.06%BlackRock Inc
6.81%Vanguard Group Inc
6.38%Westfield Capital Management Company, LP
4.76%Maverick Capital Ltd
4.32%
Company Information
rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.
Organization | Rocket Pharmaceuticals Inc |
Employees | 268 |
CEO | Dr. Gaurav D. Shah M.D. |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$17.55
-6.75%
Invesco Bulletshares 2025 Hi
$17.55
-6.75%
Schwab International Dividend Equity Etf
$17.55
-6.75%
Blockchain Coinvestors Acquisition Corp.
$17.55
-6.75%
Allgiant Travel Company
$17.55
-6.75%
Rogers Corp
$17.55
-6.75%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$17.55
-6.75%
Iheartmedia
$17.55
-6.75%
Lightpath Technologies Inc
$17.55
-6.75%